Profil bibliographique

Phillip M. Brailey

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

44Publications signalées

181Citations signalées

1Affiliations récentes

Les institutions déclarées

Les domaines associés

Peptidase Inhibition and AnalysisCancer Immunotherapy and BiomarkersCancer, Stress, Anesthesia, and Immune ResponseProstate Cancer Treatment and ResearchImmunotherapy and Immune Responses

Les publications récentes

Accès ouvert 2025 article OpenAlex

An affinity-modulated T cell engager targeting Claudin 18.2 shows potent anti-tumor activity with limited cytokine release

Miguel B. Gaspar, Marina Natoli, Laure Castan, Sharif Rahmy et autres

gb, us, cn, kr, ch, es, br (code pays fourni par la source)

7 citations Journal for ImmunoTherapy of Cancer

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 10 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 9 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 other OpenAlex

Data from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

gb (code pays fourni par la source)

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplemental Methods 1 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 3 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 8 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 11 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Accès ouvert 2024 supplementary-materials OpenAlex

Supplementary Figure 5 from CB307: A Dual Targeting Costimulatory Humabody VH Therapeutic for Treating PSMA-Positive Tumors

Sophie Archer, Phillip M. Brailey, Minjung Song, Phillip D. Bartlett et autres

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.